Evidence map›Paper›PMID 37228628›Full record

ArticleIranian journal of biotechnology2023

Response Surface Methodology to Optimize the Expression Efficiency of Recombinant Reteplase.

Farhad Farzaneh, Sako Mirzaie, Ehsan Dehnavi, Mojtaba Aghaeepoor, Shirin Farzaneh, Navid Pourzardosht, Saeed Khalili

Open access · greenAbstract read
In one paragraph

Article in Iranian journal of biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Enhancing3 Biotech · 2025
    Article
  3. Article
  4. The Induction of L-lysine-α-Oxidase fromAvicenna journal of medical biotechnology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Farhad FarzanehDepartment of Biochemistry, Faculty of Science, Sanandaj Branch, Islamic Azad University, Sanandaj, Iran.
Sako MirzaieDepartment of Biochemistry, Faculty of Science, Sanandaj Branch, Islamic Azad University, Sanandaj, Iran.
Ehsan DehnaviGene Transfer Pioneers (GTP) Research Group, Shahid Beheshti University of Medical Sciences. Tehran, Iran.
Mojtaba AghaeepoorGene Transfer Pioneers (GTP) Research Group, Shahid Beheshti University of Medical Sciences. Tehran, Iran.
Shirin FarzanehPharmaceutical Science Research Centre, Tehran medical Science, Islamic Azad University, Tehran, Iran.
Navid PourzardoshtCellular and Molecular Research Center, Faculty of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Saeed KhaliliDepartment of Biology Sciences, Shahid Rajaee Teacher Training University, Tehran, Iran.
Guilan University of Medical Sciences · IRShahid Rajaee Teacher Training University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Over expression of Reteplase enzyme has already been studies in the periplasmic space of Objectives: Optical cell density (OD), IPTG concentration, and expression time are highly effective in the protein expression rates. Therefore, we aimed to determine the optimum levels of these factors for reteplase expression using response surface methodology (RSM). Materials and Methods: The pET21b plasmid was used to sub-clone the designed reteplase gene. Then, the gene was transformed into Results: Sequence optimization removed all undesirable sequences of the designed gene. Transformation into Conclusion: The obtained results indicate that IPTG concentration, OD, and expression time are significantly involved in the augmentation of recombinant reteplase expression. To the best of our knowledge, this is the first study to assess the combined effect of these factors on reteplase expression. Further RSM-based experiments would bring about new insights regarding the best conditions for reteplase expression.

Indexed as

Gene expressionProteinReteplaseTissue plasminogen activator

Identifiers

PMID37228628
PMCPMC10203180
OpenAlexW4378347897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.